Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 139 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Regulatory T Cells Clear all

Conditions: Inclusion Body Myositis
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Kansas City, Kansas • Baltimore, Maryland

Conditions: Graft Versus Host Disease
Interventions: Cultured Treg cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Rejection of Renal Transplant, Graft Failure
Interventions: Donor-derived cell-free DNA; Diagnostic Test
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Graft Versus Host Disease
Interventions: Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Follicular Lymphoma
Interventions: Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy; Biological · Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Disorders
Interventions: ARA C, Cyclophosphamide, MESNA, Total Body Irradiation (TBI), Campath-1h, Stem Cell Infusion; Drug · Radiation · Biological + 1 more
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Interleukin-2 (aldesleukin).; Drug
Lead sponsor: Scott B. Snapper, MD PHD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions: cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation; Drug · Procedure · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: SBT777101; Biological
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more

Conditions: Kidney Failure, Kidney Transplant
Interventions: T Regulatory Cell Infusion; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergy
Interventions: Blood Sampling; Other
Lead sponsor: Adiga Life Sciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Upland, California • Fairfax, Virginia

Conditions: Coronary Artery Disease, Cardiovascular Disease
Interventions: Vitamin D, No medication; Dietary Supplement · Other
Lead sponsor: Creighton University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138; Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more

Conditions: Graft Versus Host Disease (cGvHD)
Interventions: EVE-Treg; Biological
Lead sponsor: Sarah Nikiforow, MD; Other
Eligibility: 2 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: cyclophosphamide, Mature dendritic cell vaccine; Drug · Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin, Acute Lymphoblastic Leukemia (ALL), Myeloproliferative Syndrome, Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
Interventions: CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon), Myeloablative Conditioning Regimen; Biological · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 73 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, Anemia, Refractory, With Excess of Blasts, Chronic Myeloproliferative Disease, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Lymphoma, Large Cell Non-Hodgkin's Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, High Grade Non-Hodgkin's Lymphoma
Interventions: Treg cells, CD3+ Teff cells, Fludarabine, Cyclophosphamide, Total body irradiation, Umbilical cord blood transplantation; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions: Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Relapsed Acute Myeloid Leukemia
Interventions: Flotetuzumab, Donor lymphocyte infusion; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: KIDNEY TRANSPLANTATION
Interventions: Basiliximab, Thymoglobulin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Transplantation
Interventions: aldesleukin; Biological
Lead sponsor: Anil K. Chandraker, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Phase III Trial of Sirolimus in IBM

Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

Low Dose IL-2 for Ulcerative Colitis

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

Vitamin D and T-Regulatory Cells in Coronary Artery Disease

PRE-ISPY Phase I/II Oncology Platform Program

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation